The recent AD/PD conference showcased several highlights in the field of Alzheimer’s disease (AD) and Parkinson’s disease (PD) research. Tiago Outeiro, PhD, from the University Medical Center Göttingen in Germany, highlighted the focus on biomarker research, which generated considerable excitement among attendees. Of particular importance are the recent advancements in alpha-synuclein seed amplification assays and neuroimaging assays. These innovative diagnostic/prognostic tools hold great promise in enabling early detection of diseases and improving patient stratification for future clinical trials. The promising results of lecanemab, newly approved for the treatment of AD, were also a notable taking point. Looking ahead, it was announced that the next AD/PD conference is scheduled to take place in Lisbon, Portugal in March 2024.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.